Client case study
Due Diligence of Early-Stage Cell Therapy Asset
Market landscape and competitive assessment to inform an asset purchase decision for a large biotech company.
Our client was facing a short deadline to make a decision whether to in-license a pre-clinical cell therapy asset with a novel mechanism of action. This was a large and dynamic market with considerable competitive pressure, as well as complex and unclear commercial and regulatory considerations.
Our client needed a granular understanding of the current market situation as well as market potential in specific indications of interest. A review of the competitive drug landscape as well as forecasts for the drug treatable patient pool and commercial potential would support validation of the asset and inform a go/no-go decision on the acquisition.
Result
We assessed the entire landscape and identified a number of key competitive programs that represent a potential threat to the asset of interest.
Our holistic evaluation of these highly relevant programs allowed our client to determine the extent and quality of competition in the space, clearly highlighting the relative benefits and limitations of the technology under evaluation.
Our assessment of the market potential of the technology, in the context of the competitive and scientific assessment, provided a comprehensive body of evidence that allowed the deal team to make a final decision on the asset purchase with clarity and confidence.
